A Phase 3, Multicenter, Randomized, Open-Label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) versus Docetaxel in Previously Treated Participants with Metastatic Non-Small

Grants and Contracts Details

StatusFinished
Effective start/end date12/4/19 → 3/1/22

Funding

  • Merck Sharp & Dohme Corporation: $28,794.00